Camurus ABCAMRF 81 Return-on-Tangible-Asset is 11.90% as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $73.90 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Camurus AB ranks better than 93.3% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Camurus AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $61.7 Mil. Camurus AB's average total tangible assets for the quarter that ended in Mar. 2026 was $518.8 Mil. Therefore, Camurus AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 11.90%.
The historical rank and industry rank for Camurus AB's Return-on-Tangible-Asset or its related term are showing as below:
CAMRF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -58.09 Med: -10.12 Max: 27.25
Current: 15.09
During the past 13 years, Camurus AB's highest Return-on-Tangible-Asset was 27.25%. The lowest was -58.09%. And the median was -10.12%.
CAMRF's Return-on-Tangible-Asset is ranked better than 93.3% of 1417
companies
in the Biotechnology industry
Industry Median: -35.77
vs CAMRF: 15.09
Camurus AB (OTCPK:CAMRF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Camurus AB Return-on-Tangible-Asset Related Terms
Camurus AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Camurus AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Camurus AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Camurus AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 11.90% mean?
Camurus AB (CAMRF) has a Return-on-Tangible-Asset of 11.90% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #95 out of 1417 companies in the Biotechnology industry, placing it in the top 6.7%.
Is Camurus AB's Return-on-Tangible-Asset too high?
Camurus AB's current Return-on-Tangible-Asset is 11.90%. Based on the distribution chart, Camurus AB ranks #95 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #95 out of 1417 companies for Return-on-Tangible-Asset. This places Camurus AB in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Camurus AB and its competitors. Camurus AB's current Return-on-Tangible-Asset is 11.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $73.90, compared to a current price of $61.01 — trading 17.4% below its estimated fair value. The current Return-on-Tangible-Asset is 11.90%. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Return-on-Tangible-Asset is 11.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $61.01 is trading 17.4% below its estimated GF Value™ of $73.90.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Return-on-Tangible-Asset: 11.90%
GF Value™: $73.90 vs. price of $61.01 (17.4% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
